FB-TW

Showing posts with label MI. Show all posts
Showing posts with label MI. Show all posts

Tuesday, July 2, 2013

Effect Chelation Regimen on Cardiovascular Events in Patients With Previous Myocardial Infarction - JAMA

ABSTRACT 

 
 
Importance  Chelation therapy with disodium EDTA has been used for more than 50 years to treat atherosclerosis without proof of efficacy.

Objective  To determine if an EDTA-based chelation regimen reduces cardiovascular events.

Design, Setting, and Participants  Double-blind, placebo-controlled, 2 × 2 factorial randomized trial enrolling 1708 patients aged 50 years or older who had experienced a myocardial infarction (MI) at least 6 weeks prior and had serum creatinine levels of 2.0 mg/dL or less. Participants were recruited at 134 US and Canadian sites. Enrollment began in September 2003 and follow-up took place until October 2011 (median, 55 months). Two hundred eighty-nine patients (17% of total; n=115 in the EDTA group and n=174 in the placebo group) withdrew consent during the trial.

Interventions  Patients were randomized to receive 40 infusions of a 500-mL chelation solution (3 g of disodium EDTA, 7 g of ascorbate, B vitamins, electrolytes, procaine, and heparin) (n=839) vs placebo (n=869) and an oral vitamin-mineral regimen vs an oral placebo. Infusions were administered weekly for 30 weeks, followed by 10 infusions 2 to 8 weeks apart. Fifteen percent discontinued infusions (n=38 [16%] in the chelation group and n=41 [15%] in the placebo group) because of adverse events.

Main Outcome Measures  The prespecified primary end point was a composite of total mortality, recurrent MI, stroke, coronary revascularization, or hospitalization for angina. This report describes the intention-to-treat comparison of EDTA chelation vs placebo. To account for multiple interim analyses, the significance threshold required at the final analysis was P = .036.

Results  Qualifying previous MIs occurred a median of 4.6 years before enrollment. Median age was 65 years, 18% were female, 9% were nonwhite, and 31% were diabetic. The primary end point occurred in 222 (26%) of the chelation group and 261 (30%) of the placebo group (hazard ratio [HR], 0.82 [95% CI, 0.69-0.99]; P = .035). There was no effect on total mortality (chelation: 87 deaths [10%]; placebo, 93 deaths [11%]; HR, 0.93 [95% CI, 0.70-1.25]; P = .64), but the study was not powered for this comparison. The effect of EDTA chelation on the components of the primary end point other than death was of similar magnitude as its overall effect (MI: chelation, 6%; placebo, 8%; HR, 0.77 [95% CI, 0.54-1.11]; stroke: chelation, 1.2%; placebo, 1.5%; HR, 0.77 [95% CI, 0.34-1.76]; coronary revascularization: chelation, 15%; placebo, 18%; HR, 0.81 [95% CI, 0.64-1.02]; hospitalization for angina: chelation, 1.6%; placebo, 2.1%; HR, 0.72 [95% CI, 0.35-1.47]).

Sensitivity analyses examining the effect of patient dropout and treatment adherence did not alter the results.

Conclusions and Relevance  Among stable patients with a history of MI, use of an intravenous chelation regimen with disodium EDTA, compared with placebo, modestly reduced the risk of adverse cardiovascular outcomes, many of which were revascularization procedures. These results provide evidence to guide further research but are not sufficient to support the routine use of chelation therapy for treatment of patients who have had an MI.
==================================================================
Read the complete article here.
 

Saturday, October 20, 2012

Look AHEAD halted: Lifestyle management fails to reduce hard CV outcomes in diabetics - O'Riordan

Look AHEAD halted: Lifestyle management fails to reduce hard CV outcomes in diabetics


October 19, 2012
A large cardiovascular-outcomes study funded by the National Institutes of Health that included 5145 adults with diabetes and a body mass index >25 kg/m2, Look AHEAD failed to show a difference in the rate of nonfatal MI, nonfatal stroke, death, or hospitalization for angina among patients randomized to an intensive lifestyle intervention and those randomized to a control arm consisting of education alone.
 
Despite significant reductions in weight and improvements in physical-fitness levels among patients with diabetes, investigators concluded that the intervention arm, which included individual sessions with a nutritionist and/or personal trainer, as well as group sessions and refresher courses, failed to provide any benefit in terms of cardiovascular outcomes.
 
Dr Anne Peters (University of Southern California, Los Angeles), one of the study investigators, said in an interview that the trial was successful on one level—namely, that patients lost weight and improved their fitness. Data published at four years showed that the intensive intervention led to weight loss of up to 10% in the first year and that patients maintained a 6.5% reduction in body weight in the following three years. Over an 11-year follow-up period, the patients reported a 5% reduction in body weight from baseline, said Peters.
 
In addition, early data showed that treadmill fitness levels, hemoglobin A1c levels, systolic and diastolic blood pressure, HDL-cholesterol levels, and triglyceride levels were all significantly improved among patients in the lifestyle-intervention arm when compared with the control group. The only cardiovascular risk factor that remained unchanged with treatment was LDL-cholesterol levels.
 
Despite the lack of cardiovascular benefit observed in Look AHEAD, Peters stressed that diabetic patients should not stop exercising or begin eating anything they wish.
 
"We do know that weight loss and exercise can prevent diabetes," said Peters. "I am a big advocate of prevention, both early prevention of obesity altogether, as well as prevention of diabetes in individuals who have become overweight. Lifestyle changes can help prevent diabetes. Once you have diabetes, I think weight loss and exercise can have benefits, but they are not going to reduce the risk for the primary outcome that we set for Look AHEAD, which was a risk for macrovascular events or death."
====================================================================
Read the full article here.
.
.
.

Here is the official stated purpose of the Look AHEAD trial.

The primary objective of Look AHEAD is to examine, in overweight volunteers with type 2 diabetes, the long-term effects of an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity. This program will be compared to a control condition involving a program of diabetes support and education.
The primary hypothesis is that the incidence rate of the first post-randomization occurrence of a composite outcome, which includes
  • cardiovascular death (including fatal myocardial infarction and stroke),
  • non-fatal myocardial infarction,
  • hospitalized angina, and
  • non-fatal stroke,
over a planned follow-up period of up to 13.5 years will be reduced among participants assigned to the Lifestyle Intervention compared to those assigned to the control condition, Diabetes Support and Education.

 
Look AHEAD will also test for reductions in the incidence of three secondary composite outcomes and examine the effect of the intervention on cardiovascular disease risk factors, diabetes control and complications, general health, and quality of life, and psychological outcomes. The cost and cost-effectiveness of the Lifestyle Intervention relative to Diabetes Support and Education will be assessed.
=================================================
from https://www.lookaheadtrial.org/public/home.cfm

A comment by Dr. Jack Kruse had this to say about the trial...


Jack Kruse said...

You said, you could not find all cause mortality data for the stop. Not surprising to some of us. The trial was stopped because their hypothesis was being demolished. You and I both know it. But this post further supports my concerns with RCT and so called evidence based medicine. The modern health care complex trump this brand of medicine. I loathe it. There is nothing more dangerous to modern humans than evidence based medicine and we all remain unaware of those pitfalls. Peter has touched on just that here.

I wrote very recently in my Brain Gut 14 blog this: The manner in which we ask questions is deeply flawed in medicine. Here is where the major causative factor lies in medicine that too few are talking about in research literature. You need to know it. Positive findings, whether they are good or bad for our biology, are twice as likely to be published as negative findings.

This dramatically skews the meaning of what the evidence is really showing us in medicine. It is at the core why people do not get better with evidence based practices and remain a medical annuity for the system. This is a cancer at the core evidence-based medicine today. When you become aware of what you do not know, it becomes easier to get to optimal. They key is for you to avoid those pitfalls before you access the healthcare system. Unfortunately, physicians are paid on this data and that is why it appears to many people that doctors just don’t get it. Many of us do get it, but if we step out of line we get punished by the system. That is how I feel about this Look Ahead nonsense. I am more cynical than Peter. I think the trial was ended because a current growth industry in healthcare might have been placed in peril if the trial continued.
=================================================
from HyperLipid.

Thursday, September 13, 2012

Association Between Omega-3 Fatty Acid Supplementation & Risk of Major Cardiovasular Disease - Harris

Comment On JAMA publication by Rizo et.al: Association Between Omega-3 Fatty Acid Supplementation & Risk of Major Cardiovasular Disease

Response on the JAMA publication: Association Between Omega-3 Fatty Acid Supplementation and Risk of Cardiovascular Disease Events: On September 12, 2012 Rizos et al. published a meta-analysis titled: “Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events” on fish oil and concluded no benefit. Spokespeople from the AHA have been on TV saying that omega-3 supplements clearly don’t ‘work’. here are some of my thoughts…

Positve view of the study

They included all relevant studies; they did not exclude (like the previous meta-analysis (Kwak) did) the non-placebo controlled trials (GISSI-Prevenzione and JELIS)

First negative view about the study


They showed in Figure 3 that there was a significant benefit of omega-3 on cardiac death, and trends towards benefit in total mortality, sudden death and MI (plus trends towards increased stroke). But in the text, they said that there was NO significant effect on cardiac death – this is because they set the p-value for significance at 0.006, a much higher hurdle (than the usual 0.05) for concluding benefit. In my view, this is completely inappropriate and excessively conservative, especially for a very safe intervention. In other words, if you are testing a new drug that has potential benefits AND side/adverse effects, then you want to be very conservative in concluding “benefit” (i.e., you want to require a very small p-value) since – if you’re wrong and the drug really isn’t helpful (false positive) - your ‘endorsement’ of the drug will lead to increased use and thus the potential for increased adverse effects. However, for very low risk interventions (n-3 fatty acids), you don’t worry about adverse effects… you want people to use the treatment even if there is only a trend towards benefit. A favorable benefit-risk ratio. (I’d even suggest that in this setting, a p-value for ‘significant effect’ should be 0.1 instead of the traditional 0.05). In addition, nobody I know of ever adjusts for multiple testing (sets a lower p-value than 0.05 as the target for significance) in a meta-analysis. Therefore, I believe that the authors were far too conservative in this analysis, which led to their “no benefit” conclusion.

Second negative view about the sudy


They should have been much more nuanced in their conclusions. They said, “Our findings do not justify the use of omega-3 in structured [?] intervention in everyday clinical practice or guidelines supporting dietary omega-3 PUFA administration.” They should have said, “In patients of average age 63, with existing cardiovascular disease and under optimal medical care (which, by the way, is very UNcommon), the administration of about 1 g of EPA+DHA for 4 years will not affect major clinical outcomes.” Their study does NOT show that treating with a higher dose for a longer period of time, or treating patients earlier in the disease process or those who are not receiving “optimal medical therapy” will NOT be beneficial.

There may (or may not!) be a slight silver lining to all of this: Here is what Tom Barringer and I ended a chapter on n3 and CVD with in an upcoming book on “Omega-3 Deficiency”:
It should be stressed that future research will be significantly hampered if clinicians and patients are dogmatic in their belief that the value of n-3 fatty acids in CVD is already well-established. If such unfounded certainty is widespread, it will become very difficult to find patients (and investigators and IRBs) willing to participate in or approve the placebo-controlled clinical trials that are so desperately needed to properly evaluate the value of these nutrients in the treatment and prevention of CVD.”
Clearly with Rizos’ paper, we now won’t have any problem convincing the world that the question of omega-3s and CHD risk is still open.

In summary, they were too conservative in their analysis and they were not thoughtful in drawing their conclusions. It’s quite likely true that 1 g of EPA+DHA won’t affect outcomes over a few years in older people started later in life who are well-treated pharmacologically – but that’s a far cry from USA Today’s Headline “Fish oil pills with omega-3 don’t help against disease”
==================================================================

William Harris PhDWilliam Harris PhD
Senior Scientist
William Harris holds a PhD in Nutritional Biochemistry from the University of Minnesota, and did 4 years of post-doctoral research at the Oregon Health Sciences University. He was Director of the Lipid Research Laboratories at the University of Kansas Medical Center (KUMC) and at the Mid America Heart Institute, both in Kansas City, MO, for 22 years, and was on the faculty at KUMC and at the University of Missouri-Kansas City School of Medicine. Between 2006 and 2011 was the Director of the Cardiovascular Health Research Center at Sanford Research/USD (Sioux Falls, SD).
============================================================

Read the complete article here.